NCT03911557View on ClinicalTrials.gov

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 8, 2019

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Tumor, Solid
Interventions
DRUG

Durvalumab and Tremelimumab

Durvalumab 1500mg + tremelimumab 75mg via IV infusion Q4W, starting on Week 1, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 2 years of total therapy.

Trial Locations (1)

40536

Markey Cancer Center, Lexington

All Listed Sponsors
lead

John L. Villano, MD, PhD

OTHER